Acurx Pharmaceuticals (NASDAQ:ACXP) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Acurx Pharmaceuticals (NASDAQ:ACXP) from a sell rating to a hold rating in a report published on Saturday.

A number of other research firms also recently weighed in on ACXP. Weiss Ratings reiterated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Wednesday. HC Wainwright reiterated a “buy” rating and set a $31.00 target price on shares of Acurx Pharmaceuticals in a report on Tuesday, September 30th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $31.00.

Acurx Pharmaceuticals Price Performance

ACXP opened at $7.48 on Friday. The business has a 50 day simple moving average of $4.69 and a two-hundred day simple moving average of $7.03. The firm has a market capitalization of $11.82 million, a price-to-earnings ratio of -0.70 and a beta of -1.29. Acurx Pharmaceuticals has a one year low of $3.80 and a one year high of $42.80.

Acurx Pharmaceuticals (NASDAQ:ACXP) last released its quarterly earnings results on Monday, August 11th. The company reported ($1.89) EPS for the quarter, beating analysts’ consensus estimates of ($2.00) by $0.11. As a group, sell-side analysts expect that Acurx Pharmaceuticals will post -0.89 EPS for the current fiscal year.

Institutional Trading of Acurx Pharmaceuticals

A hedge fund recently bought a new stake in Acurx Pharmaceuticals stock. Armistice Capital LLC purchased a new position in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,078,540 shares of the company’s stock, valued at approximately $551,000. Armistice Capital LLC owned about 70.13% of Acurx Pharmaceuticals as of its most recent SEC filing. Institutional investors own 11.53% of the company’s stock.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.